CD44 and prostate carcinoma: Since it has been reported that CD133 is a robust biomarker for prostate cancer stem cells, a combination of CD133+ and CD44+ markers, with or without integrin 21, may further improve the isolation of prostate cancer stem cells from clinical specimens [29].